Worldwide Biotech/Biopharma Alliance (Apr. 12, 2013～Apr. 8, 2013)
On Apr. 12, 2013, Carbios announced the signature of a pivotal €7-million collaboration with the French National Institute for Agricultural Research (INRA) at the Toulouse White Biotechnology (TWB) research center. The INRA groups will focus on enzyme screening, enzymatic catalysis and cell engineering.
>On Apr. 9, 2013, GlaxoSmithKline (GSK) and A*STAR’s Institute of Chemical and Engineering Sciences (ICES) signed a five-year strategic agreement to develop new evidence based formulations (EBFs) specifically for emerging markets. EBFs are medicines which are reformulated to provide additional patient benefit.
>On Apr. 9, 2013, Proteros biostructures GmbH ("Proteros") announced that it has entered into a Lead Discovery Collaboration with Priaxon AG to jointly develop lead compounds for high value protein-protein interaction (PPI) drug targets. Their collaboration will focus on the identification of novel small molecule modulators for PPI targets.
>On Apr. 9, 2013, Inventiva and NovAliX announced that they have entered into a strategic alliance dedicated to the discovery of clinical candidates, targeting nuclear receptors. After several years of successful collaboration in the field of nuclear receptors and a proven track record with three programs having reached clinical stage, Inventiva and NovAliX are now officially teaming up to establish a solid alliance to further deliver on the therapeutic promises of the nuclear receptor target class.
On Apr. 8, 2013, In Tech Open Access publisher announced its collaboration with the American Society for Exosomes and Microvesicles (ASEMV) to publish the scientific journal Exosomes and Microvesicles, a peer-reviewed publication designed to bring together exosomes principles, scientific research and clinical applications. The Exosomes and Microvesicles journal is one of the first publications to focus exclusively on this subject matter, which has important implications for treating diseases such as cancer. Despite the past decade's explosion of research within the fields of exosomes, microvesicles and other extracellular vesicles, access to this data is often limited – thus impacting further advancements in human health. As the official journal of the ASEMV, Exosomes and Microvesicles will provide open access to global data, supporting the organization's mission to advance extracellular vesicle research and support the scientists, institutions and laboratories working in this field.